Previous 10 | Next 10 |
The following slide deck was published by Agilent Technologies, Inc. in conjunction with this event. For further details see: 2023-Agilent-JP-Morgan-Presentation_with-Recons
Agilent Technologies, Inc. (A) Goldman Sachs Healthcare CEOs Unscripted Conference January 05, 2022 2:05 PM ET Company Participants Mike McMullen – Chief Executive Officer Bob McMahon – Chief Financial Officer Conference Call Participants Matt Syk...
Agilent Technologies ( NYSE: A ) and Bio-Techne Corporation ( NASDAQ: TECH ) traded higher on Tuesday after Wells Fargo upgraded both life sciences stocks despite maintaining a negative Pharma/Biotech outlook. The analyst Timothy Daley sees late-cycle headwinds to Pharma/Biote...
Summary Agilent shows growth in all its end markets, providing the company with positive core revenue growth. It shows margin expansion and has a positive cash flow outlook from the management. The company does disclose certain growth concerns that put its premium valuation into que...
The board of directors of Agilent Technologies ( NYSE: A ) has a uthorized a stock repurchase of up to $2B of the company's shares. The program will begin on March 1. Agilent ( A ) had an existing buyback program, but this new one replaces it. See why Seeking Alp...
Agilent Technologies Inc. (NYSE: A) today announced that its board of directors has approved a new share repurchase program. The 2023 program authorizes the purchase of up to $2 billion of the company’s common stock. “Agilent is committed to balanced capital deployment that driv...
Agilent Technologies ( NYSE: A ) on Monday said it would invest $725M to double its manufacturing capacity to produce nucleic acid-based therapeutics. The company has proposed the expansion through two new manufacturing lines at its facility in Frederick, Colo., and expects ...
Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases Agilent Technologies Inc. (NYSE: A) today announced it is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in r...
Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...
Will commercialize end-to-end workflow solutions for tissue biomarker analysis in companion diagnostic development Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiple...
News, Short Squeeze, Breakout and More Instantly...
Agilent Technologies Inc. Company Name:
A Stock Symbol:
NYSE Market:
Agilent Technologies Inc. Website:
Expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturin...
2024-07-21 07:07:00 ET At long last, Europe has a space rocket, the Ariane 6, able to compete with SpaceX and its ubiquitous Falcon 9. The Ariane 6 isn't a reusable rocket, it arrived four years later than it was supposed to, and it probably costs about twice as much as a Falcon. But fo...
Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2024 after the stock market closes on Aug. 21. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT. To join the listen-only conference call webcast,...